List of Excipients in Branded Drug OFLOXACIN

« Back to Dashboard

Generic Drugs Containing OFLOXACIN

Company	Ingredient	NDC	Excipient
Henry Schein Inc	ofloxacin	0404-7189	BENZALKONIUM CHLORIDE
Henry Schein Inc	ofloxacin	0404-7189	HYDROCHLORIC ACID
Henry Schein Inc	ofloxacin	0404-7189	SODIUM CHLORIDE
Henry Schein Inc	ofloxacin	0404-7189	SODIUM HYDROXIDE
Henry Schein Inc	ofloxacin	0404-7189	WATER

What are the Most Frequently-Used Excipients in OFLOXACIN?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	AQUA
117	BENZALKONIUM CHLORIDE
2	BUTYL ALCOHOL
2	FD&C BLUE NO. 1

Ofloxacin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Ofloxacin is a mature fluoroquinolone with limited composition-of-matter patent value and substantial generic competition. Commercial opportunity is concentrated in differentiated delivery, preservative systems, pediatric and otic formulations, manufacturing efficiency, and regional supply rather than in a new-molecule strategy.

The principal dosage forms are oral tablets, ophthalmic solution, and otic solution. The most commercially practical development paths are:

• Preservative-free or low-preservative ophthalmic products
• Unit-dose ophthalmic and otic packaging
• Improved otic suspensions or gel-forming systems
• Pediatric-friendly oral liquids or dispersible tablets
• Cost-optimized generic tablets
• Combination products with validated antimicrobial or anti-inflammatory positioning
• Regional products targeting markets where ofloxacin remains widely used

Ofloxacin is available in 200 mg, 300 mg, and 400 mg oral tablets, commonly as a 0.3% ophthalmic solution and as a 0.3% otic solution. FDA labeling identifies mature products and generic pathways, with no meaningful new-drug exclusivity remaining for the active ingredient.[1-4]

What pharmaceutical products contain ofloxacin?

Ofloxacin products use the same active pharmaceutical ingredient but require different excipient strategies because oral, ophthalmic, and otic products have different performance, sterility, tolerability, and packaging requirements.

Dosage form	Typical strength	Primary use	Key formulation constraints
Immediate-release tablet	200, 300, 400 mg	Systemic bacterial infections	Compression, dissolution, content uniformity, taste is less important
Ophthalmic solution	0.3%	Bacterial eye infections	Sterility, clarity, pH, osmolality, preservative tolerance
Otic solution	0.3%	Otitis externa and selected middle-ear infections	Sterility, local tolerability, drop delivery, container compatibility
Oral liquid or dispersible product	Not a dominant U.S. reference format	Pediatric or swallowing-challenged populations	Taste masking, suspension stability, dosing accuracy

A 0.3% solution contains 3 mg/mL ofloxacin. A 5 mL bottle therefore contains approximately 15 mg of active ingredient before accounting for overfill.

What excipients are used in ofloxacin formulations?

Commercial ofloxacin products generally use established excipients rather than novel delivery systems. The most relevant excipient classes are buffers, tonicity agents, preservatives, solubilizers, binders, disintegrants, lubricants, film coatings, and viscosity modifiers.

Oral tablet excipients

Legacy ofloxacin tablet formulations have used combinations such as:

• Lactose or another filler
• Microcrystalline cellulose
• Croscarmellose sodium as a disintegrant
• Hydroxypropyl cellulose or hypromellose as a binder
• Magnesium stearate as a lubricant
• Poloxamer-type surfactants in selected formulations
• Hypromellose-based film coating
• Titanium dioxide and other approved colorants

The commercial objective for an immediate-release tablet is usually low-cost reproducibility rather than extended release. Ofloxacin has high oral bioavailability, reported at approximately 98% in product labeling, which reduces the commercial need for a complex oral delivery platform.[1]

Ophthalmic excipients

Ofloxacin ophthalmic solution commonly uses:

• Sodium chloride for tonicity
• Benzalkonium chloride as a preservative in multidose products
• Hydrochloric acid and sodium hydroxide for pH adjustment
• Purified or sterile water as the vehicle

FDA labeling for Ocuflox identifies a sterile 0.3% solution and includes benzalkonium chloride at 0.005% in the formulation.[2] The product is designed for topical ocular delivery, where clarity, sterility, pH, osmolality, and preservative tolerance control commercial viability.

Otic excipients

Ofloxacin otic products commonly contain:

• Sodium chloride
• Benzalkonium chloride in multidose presentations
• Purified water
• pH-adjusting agents where needed

The absence of a suspension vehicle makes a clear solution easier to manufacture and fill than many alternative otic products. The main differentiation opportunity is therefore in preservative strategy, packaging, delivery accuracy, and patient usability rather than in basic solubilization.

Which excipient attributes matter most for ofloxacin?

Excipient selection should be driven by the dosage form and target market.

Attribute	Oral tablets	Ophthalmic solution	Otic solution
Chemical compatibility	High priority	High priority	High priority
Sterility	Not applicable to conventional tablets	Critical	Critical
Preservative tolerance	Usually irrelevant	Critical for multidose products	Important
Taste masking	Moderate for pediatric products	Not applicable	Low
Viscosity control	Low	Moderate	Moderate
Container interaction	Moderate	High	High
Dose uniformity	Critical	Critical	Critical
Patient comfort	Moderate	Very high	High
Cost pressure	Very high	High	High

Ofloxacin is a weakly basic fluoroquinolone with pH-dependent solubility behavior. Formulators must control pH without causing ocular or otic irritation. Excessive use of surfactants, preservatives, or viscosity agents can impair tolerability even when the active ingredient remains chemically stable.

What formulation patents protect ofloxacin products?

Most ofloxacin composition-of-matter protection has expired. Current commercial barriers are more likely to involve formulation, manufacturing process, packaging, device, or combination-product claims than the ofloxacin molecule itself.

Relevant patent categories include:

• Preservative-free ophthalmic solutions
• Multidose containers with antimicrobial protection
• Gel-forming ophthalmic or otic systems
• Controlled-release oral formulations
• Taste-masked pediatric suspensions
• Combination products containing ofloxacin and corticosteroids
• Manufacturing processes that improve impurity control
• Container-closure systems that improve sterility or dosing accuracy

A patent covering a particular excipient combination may have limited practical value if competitors can design around it with a different buffer, preservative, viscosity modifier, or packaging configuration. For a mature active ingredient, enforceability depends heavily on whether the claims require a narrow pH range, specific preservative concentration, defined particle size, stability profile, or container structure.

The FDA Orange Book should be reviewed product by product for listed patents and regulatory exclusivity. A search for ofloxacin should distinguish oral products from ophthalmic products and from otic products because listing practices and reference products differ by dosage form.[5]

When does ofloxacin lose exclusivity?

Ofloxacin has already lost practical U.S. market exclusivity. The original branded systemic product, Floxin, was approved decades ago, and generic competition has been established for oral, ophthalmic, and otic products.

Protection category	Current commercial position
Active-ingredient exclusivity	Expired
Original new-drug exclusivity	Expired
Oral generic entry	Established
Ophthalmic generic entry	Established
Otic generic entry	Established
New formulation patents	Product-specific and must be verified in current records
Pediatric exclusivity	No general current exclusivity advantage
Biosimilar exclusivity	Not applicable

Ofloxacin is a small-molecule antibiotic, not a biologic. Biosimilar regulation does not apply. Competitive entry proceeds through abbreviated new drug applications, not biosimilar applications.

What is the Orange Book status of ofloxacin?

Ofloxacin has historically been associated with several reference-listed drugs and generic products across multiple dosage forms. The most relevant FDA regulatory routes are:

• ANDA approval for therapeutically equivalent generic products
• 505(b)(2) development for materially different delivery systems or combinations
• NDA approval for a novel formulation or new clinical indication

A standard immediate-release tablet with the same active ingredient, strength, dosage form, route, and performance profile is generally an ANDA opportunity. A preservative-free multidose ophthalmic product, an extended-release tablet, or an ofloxacin-corticosteroid combination may require a more complex regulatory strategy depending on the product design and reference product.

Orange Book evaluation should confirm:

1. The currently designated reference-listed drug.
2. Whether patents are listed against the specific dosage form.
3. Whether any exclusivity remains.
4. Whether therapeutic-equivalence ratings support substitution.
5. Whether the intended product is eligible for ANDA approval or requires a 505(b)(2) pathway.[5]

What Paragraph IV challenges affect ofloxacin?

Paragraph IV litigation risk is generally low for legacy ofloxacin products because the principal molecule and original dosage forms have long been genericized. A Paragraph IV certification could still arise against a listed formulation or method-of-use patent, particularly for:

• A proprietary ophthalmic formulation
• A controlled-release oral product
• An otic combination product
• A device-enabled delivery system
• A newly approved indication with listed patent protection

For a conventional 0.3% ophthalmic solution or immediate-release tablet, the higher risk is usually regulatory and commercial rather than patent litigation. The sponsor must still confirm current Orange Book listings and any active litigation before filing.

What formulation strategies offer the strongest commercial opportunity?

Preservative-free ophthalmic ofloxacin

Preservative-free ophthalmic products can target patients with ocular-surface sensitivity, frequent dosing, contact-lens use, or chronic topical treatment exposure. The principal technical challenge is multidose microbial protection.

Commercial options include:

• Unit-dose preservative-free vials
• Multidose bottles using a validated sterile barrier or nontraditional dispensing valve
• Low-preservative formulations
• Packaging that limits backflow and microbial ingress

Unit-dose packaging raises filling and packaging costs but can support premium pricing and institutional use. The product must demonstrate sterility throughout the labeled in-use period and maintain acceptable drop size and usability.

Improved otic delivery

Otic products are suitable for delivery-system differentiation because patients often value ease of administration more than small price differences. Potential designs include:

• Dropper systems that improve dose accuracy
• Single-use vials for clinic or pediatric use
• Mildly viscous solutions that reduce runoff
• Gel-forming systems that increase residence time
• Packaging compatible with field, urgent-care, and pediatric settings

A viscosity increase must be controlled. Excess viscosity can slow dose delivery, reduce patient acceptance, or complicate manufacturing and filling.

Pediatric oral formulations

Ofloxacin is not a leading pediatric antibiotic because of fluoroquinolone safety and stewardship considerations. A pediatric oral formulation may therefore have a narrower market than a standard adult tablet. The opportunity is strongest for defined clinical situations where fluoroquinolone therapy is justified and a liquid or dispersible format solves an administration problem.

Important excipient requirements include:

• Taste masking without excessive sugar
• Suspension stability
• Accurate dosing across the intended concentration range
• Low sedimentation and easy redispersion
• Compatibility with common oral syringes
• Preservative selection appropriate for repeated use

A liquid product would need a clear clinical and commercial rationale because the reference market is already generic and price-sensitive.

Cost-optimized tablets

The largest volume opportunity remains efficient production of immediate-release tablets. Competitive advantages can come from:

• Fewer excipients
• Direct compression where feasible
• Reduced coating complexity
• Robust dissolution performance
• High-throughput packaging
• Regional manufacturing and supply reliability

The development target should be a formulation with a broad manufacturing operating window. A low-cost formula that is sensitive to granulation moisture, compression force, or lubricant blending may create more risk than value.

How does ofloxacin compare with competing fluoroquinolones?

Ofloxacin competes with ciprofloxacin, levofloxacin, moxifloxacin, and other topical antibiotics. Its commercial position differs by dosage form.

Product attribute	Ofloxacin	Ciprofloxacin	Levofloxacin	Moxifloxacin
Oral generic maturity	High	High	High	High
Ophthalmic use	Established	Very strong	Established	Established
Otic use	Established	Established	Less central in some markets	Limited relative to ophthalmic
Formulation complexity	Low to moderate	Low to moderate	Low to moderate	Low to moderate
Brand differentiation potential	Low for tablets	Low for tablets	Low for tablets	Low for tablets
Preservative-free opportunity	Available	Available	Available	Available
Biosimilar relevance	None	None	None	None

Ciprofloxacin often has stronger recognition in bacterial eye and ear products. Levofloxacin and moxifloxacin may compete in ophthalmic products where prescribers prioritize newer fluoroquinolones or broader clinical positioning. Ofloxacin can compete through price, supply reliability, tolerability, and dosage-form convenience.

What manufacturing and intellectual-property barriers exist?

The manufacturing barriers are moderate rather than fundamental. Ofloxacin does not require biologic fermentation, cold-chain distribution, or complex device integration for conventional products.

Key manufacturing controls include:

• API identity and assay
• Related substances and degradation products
• Particle-size control where dissolution depends on API properties
• Solution clarity and absence of visible particles
• Sterility assurance for ophthalmic and otic products
• Preservative content and antimicrobial effectiveness
• Container-closure integrity
• Extractables and leachables
• Drop size and delivered-volume consistency

For ophthalmic and otic solutions, container-closure performance can be more commercially important than the excipient list. A product that uses common excipients but has a superior sterile dispensing system may obtain better customer acceptance than a nominally novel formulation.

The principal IP risk is freedom to operate around specific formulation claims, packaging claims, and combination products. Patent searches should cover the active ingredient, dosage form, excipient combinations, container systems, manufacturing processes, and relevant jurisdictions.

Which companies are competing in ofloxacin products?

Ofloxacin is supplied by a large number of generic pharmaceutical companies. Product availability varies by country and dosage form. U.S. generic competition has included companies such as Sandoz, Teva, Dr. Reddy’s Laboratories, Apotex, Mylan/Viatris, and other ANDA holders, depending on the product and time period.

Brand or legacy reference products include:

• Floxin for systemic ofloxacin
• Ocuflox for ophthalmic ofloxacin
• Floxin Otic for otic ofloxacin

The active competitive set should be determined from current FDA product databases, Drugs@FDA, the Orange Book, and commercial wholesaler listings. Company participation can change through discontinuations, divestitures, and product transfers.[2-5]

What revenue exposure exists for ofloxacin?

Revenue exposure is concentrated in low-price, high-volume generic channels. The commercial profile has four layers:

Segment	Revenue potential	Margin profile	Main risk
Oral tablets	High volume, low unit price	Low to moderate	Price erosion and substitution
Ophthalmic solution	Moderate volume	Moderate	Sterility, preservative, and supply requirements
Otic solution	Lower volume	Moderate to higher per unit	Narrower market and competition
Differentiated delivery	Lower volume initially	Potentially higher	Clinical and regulatory development cost

A conventional oral tablet launch is unlikely to create substantial value without manufacturing or distribution advantages. Ophthalmic and otic products offer better opportunities for formulation differentiation, particularly where packaging, preservative burden, or administration convenience addresses a documented user problem.

Public financial reporting generally does not isolate ofloxacin revenue by product. Company-level exposure should therefore be assessed through product listings, supply contracts, discontinuation notices, and market-share data rather than through reported segment revenue.

What generic launch scenarios exist for ofloxacin?

Scenario 1: Standard oral tablet

This is the lowest-risk regulatory route and the most competitive commercial route. The product can use a conventional immediate-release formulation and established excipients. Price competition is likely to be intense.

Scenario 2: Standard ophthalmic solution

This route offers greater commercial differentiation than tablets but requires robust sterile manufacturing, preservative control, and container validation. A conventional multidose bottle remains a defensible entry product.

Scenario 3: Preservative-free ophthalmic product

This route can command a higher price if the product demonstrates a meaningful tolerability or usability advantage. Unit-dose packaging increases operating cost and may reduce gross margin unless positioned in specialty or institutional channels.

Scenario 4: Otic solution with improved delivery

A differentiated dropper, unit-dose format, or residence-time system can create a commercial niche. The product must avoid unnecessary formulation complexity that increases regulatory burden without improving treatment use.

Scenario 5: Ofloxacin combination product

An ofloxacin-corticosteroid combination may support stronger differentiation than ofloxacin alone, but it also introduces new clinical, regulatory, stability, and IP issues. Combination products require careful assessment of active-ingredient compatibility and the applicable approval pathway.

What geographic opportunities exist for ofloxacin?

Ofloxacin remains commercially relevant in markets where generic antibiotics are widely used and ophthalmic and otic care is expanding. Opportunities may be strongest where:

• Local manufacturing is favored
• Branded generics remain commercially important
• Ophthalmic and otic products have limited supplier diversity
• Hospital tenders reward reliable supply
• Unit-dose or preservative-free formats are underdeveloped
• Regulatory pathways recognize established reference products

The U.S. market is highly genericized. Selected emerging markets may offer better branded-generic margins but carry greater risks involving price controls, regulatory variation, antimicrobial stewardship, procurement concentration, and local competition.

How strong is the patent estate for ofloxacin?

The core ofloxacin patent estate is weak from a new-molecule perspective because the active ingredient and original product categories are long established. The remaining strategic value is likely to be concentrated in narrow formulation and delivery claims.

IP layer	Relative strength
Ofloxacin molecule	Very low
Conventional oral tablet	Very low
Conventional 0.3% ophthalmic solution	Low
Conventional 0.3% otic solution	Low
Preservative-free delivery	Potentially moderate, product-specific
Novel container-closure system	Potentially moderate
Controlled-release formulation	Potentially moderate
Combination product	Moderate, depending on claims and approval date
Manufacturing process	Narrow and process-dependent

A new entrant should not rely on broad exclusivity. Value depends on regulatory execution, supply quality, formulation tolerability, and channel strategy.

Key Takeaways

• Ofloxacin is a mature generic antibiotic with no meaningful remaining molecule-level exclusivity.
• The main dosage forms are 200 mg, 300 mg, and 400 mg tablets, 0.3% ophthalmic solution, and 0.3% otic solution.
• Oral tablets are primarily a cost and supply-chain opportunity.
• Ophthalmic and otic products offer stronger formulation differentiation potential.
• Preservative-free packaging, sterile multidose systems, unit-dose delivery, and improved drop accuracy are the most credible excipient-adjacent opportunities.
• Ofloxacin is not subject to biosimilar competition because it is a small molecule.
• Paragraph IV risk is generally low for conventional products but can arise from listed formulation, delivery-device, or method-of-use patents.
• Commercial success depends more on manufacturing reliability and product usability than on broad patent protection.
• Combination products and specialty delivery systems can support stronger margins but require materially greater regulatory and clinical investment.

FAQs

Can ofloxacin be formulated as a preservative-free eye drop?

Yes. A preservative-free ophthalmic product can use unit-dose containers or a validated multidose container-closure system. The principal requirements are sterility maintenance, container integrity, drop delivery, and acceptable stability.

Is benzalkonium chloride necessary in ofloxacin ophthalmic products?

No. Benzalkonium chloride is commonly used in multidose products, but it is not inherently required. A preservative-free design must use packaging and manufacturing controls that prevent microbial contamination during the labeled use period.

Is ofloxacin suitable for an extended-release tablet?

Technically, an extended-release product is possible, but its commercial case is limited because ofloxacin already has high oral bioavailability and mature immediate-release generic competition. A new product would need a clear dosing, adherence, or tolerability advantage.

Can ofloxacin and dexamethasone be developed as a combination product?

Yes, but the combination would require evaluation of clinical justification, stability, dose selection, regulatory pathway, and freedom to operate. The commercial rationale is stronger in ophthalmic and otic products than in systemic tablets.

What is the most attractive excipient opportunity for ofloxacin?

Preservative-free ophthalmic delivery is the strongest general opportunity. It addresses a recognized formulation concern, supports differentiated packaging, and can command better economics than a conventional immediate-release tablet, although it requires higher sterile-manufacturing and packaging investment.

References

1. U.S. Food and Drug Administration. (2016). Floxin (ofloxacin) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2018). Ocuflox (ofloxacin ophthalmic solution) prescribing information. FDA.

3. DailyMed. (n.d.). Ofloxacin ophthalmic solution, 0.3%. National Library of Medicine.

4. DailyMed. (n.d.). Ofloxacin otic solution, 0.3%. National Library of Medicine.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.